The Latest DOGE Hoax Just Dropped
A Secret Service Whistleblower Dropped a Damning Account of Joe Biden at the...
Former Hamas Hostage: Things Changed Drastically Once Trump Won the 2024 Election
Elon Musk Cooked The New York Times in the Oval Office...and Trump's Reaction...
The Collapse of the COVID Vaccine Project
Following the Backside in Front of Us
Trump’s Industrial Legacy: Steel, Sovereignty, and Strength
Trump’s Executive Order Confronts a Long History of Veteran Neglect
Sen. Paul Must Help to End Nuclear Subsidies
Democrats Truly Need NPR
Putin to Skip Peace Talks As Trump Pushes for Immediate End to War
Trump Doubles Steel Tariffs to 50%, Declares End to 'Shoddy Steel from Shanghai'
Here's What's Next for DOGE
Drunk Illegal Alien Who Killed Las Vegas Police Officer Was Three Times Over...
Democrat Rep. Gabe Vasquez Joins AOC in Renewed Push to Abolish ICE
OPINION

Bipartisanship: Corporate Welfare

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.

An issue with my paper on corporate welfare in the federal budget is that cases can be made for other expenditures not on the list. A prime example would be Pentagon weapons procurement. I’ll simply say that deciding what counts and what doesn’t is complicated.

Advertisement

The New York Times has another example of what could be considered a form of corporate welfare: excessive federal reimbursement rates for anti-anemia drugs used by dialysis centers. This snippet provides the background:

The multibillion-dollar dialysis industry has been accused  by medical researchers and former employees of putting a higher priority on profits than on care before, giving patients for many years too many doses of the expensive anti-anemia drug Epogen to collect higher reimbursements — allegations the companies have strongly disputed.

The excessive payments to the companies since 2011 came about, in fact, as the federal government tried to create a single bundled payment for each patient visit. The idea was to eliminate the incentive to prescribe too many doses of Epogen, which medical research showed was harming patients.

With the profit incentive gone, use of Epogen dropped even more than the federal government expected. So the amount of money set aside in the new bundle exceeded the cost of the drugs, two separate federal audits in the last year have shown.

The industry, as a result, has collected an extra $530 million to $880 million a year in federal payments since 2011, compared with the actual use of Epogen and other dialysis drugs. That is the windfall that Congress ordered Health and Human Services to eliminate in January.

Thanks to a massive lobbying campaign from the dialysis industry ($8 million since 2009), Congress is now considering giving back the taxpayer-financed windfall. According to theTimes, “more than 100 of the same members of Congress who voted in January to impose the cut are now trying to push the Obama administration to reverse it or water it down.” Leading the charge to reverse the cuts are “lawmakers who are among the top recipients of campaign contributions from the industry, including Representatives John Lewis, a Georgia Democrat, and John M. Shimkus, an Illinois Republican, as well as Mr. [Ben] Lujan [D-NM].”

Advertisement

And, surprise, the effort is bipartisan:

The full-court press has energized Congress. A broad coalition, including conservative Republicans and liberal Democrats and many in between, has joined the industry appeal, with 205 members of the House alone signing a letter this month to the Medicare administrator asking her to reconsider the proposed cut. Half of those signers voted in favor of the cut in January.

In sum, Republicans are teaming up with Democrats to keep the taxpayer dollars flowing to a special interest.

It’s just another day in the Beltway


Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement